Ronald Levy, MD

Clinical Focus

• Cancer> Lymphoma
• Lymphoma
• Non-Hodgkin's Lymphoma
• Non-Hodgkin's Lymphoma - Medical Oncology
• Burkitt's Lymphoma

Honors and Awards

• King Faisal International Prize, King Faisal Foundation (2009)
• Member, National Academy of Sciences (2008)
• di Villiers International Achievement Award, Leukemia and Lymphoma Society (2007)
• Member, Institute of Medicine (2007)
• Damashek Prize, American Society of Hematology (2004)

Professional Education

Postdoctoral Advisees

Stacey Adam , Matthew Gubens , Jerry Hsu , Itai Kela , Atul Kumar , Yulin Li , Neta Madar , Aurelien Marabelle , Patrick Ng , Yael Sagi , Bindu Varghese

Web Site Links

• http://med.stanford.edu/labs/ronald_levy/

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Current Research Interests

Our research concentrates on the study of malignant lymphoma and tumors of the immune system using the tools of immunology and molecular biology to develop a better understanding of the initiation and progression of the malignant process. Receptor molecules present on the surface of tumor cells transmit signals for regulation of cell growth. These receptors include the immunoglobulin molecule on B cell tumors and the T cell receptor on T cell tumors. Questions the lab is currently addressing include:
1. Can a clue to the pathogenesis of lymphoma be derived from a study of their antigen receptors?
2. Can new treatments for lymphoma be developed by targeting receptors with monoclonal antibodies?
3. Can vaccines be developed which can induce an immune response in the host against the receptors on their own tumor?

Clinical Trials

• A Phase II Intratumoral Injection PF-3512676 plus Local Radiation in Low-Grade B-Cell Lymphomas Recruiting
• Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease Recruiting
• Genes in Predicting Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab and Combination Chemotherapy Recruiting
• Phase I/II of a CpG-Activated Whole Cell Vaccine Followed by Autologous “Immunotransplant” for MCL Recruiting
• Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's Lymphoma Recruiting

Publications

• Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. Brody JD, Goldstein MJ, Czerwinski DK, Levy R. Blood. 2009; 113 (1): 85-94
• T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Houot R, Levy R. Blood. 2009; 113 (15): 3546-52
• Vaccines for lymphomas: idiotype vaccines and beyond. Houot R, Levy R. Blood Rev. 2009; 23 (3): 137-42
• Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Timmerman JM, Vose JM, Czerwinski DK, Weng WK, Ingolia D, Mayo M, Denney DW, Levy R. Leuk Lymphoma. 2009; 50 (1): 37-46
• Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. Weng WK, Levy R. Leuk Lymphoma. 2009; 50 (5): 723-7